Identification and DepMap CRISPR Dependency Analysis of a Pan-Cancer Epigenomic Signature of MYC-Driven Activation
This study identifies a conserved fifteen-gene epigenomic signature characterized by concurrent upregulation and DNA hypomethylation across MYC-driven breast, liver, and colorectal cancers, revealing specific genes that correlate with poor survival and represent critical vulnerabilities for cell viability.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer is often described as a disease of broken instructions. Inside every cell, a complex set of genetic codes tells the body when to grow, when to stop, and how to function. When these instructions go wrong, cells can begin to multiply uncontrollably, forming tumors. One of the most common culprits in this process is a gene called MYC. This gene acts like a master switch, turning on a vast array of other genes that drive cell division and metabolism. In roughly seventy percent of human cancers, this switch is stuck in the "on" position. However, scientists have long struggled to understand the full picture of how MYC works. While we know it changes which genes are active, we have not fully understood how it alters the physical packaging of DNA itself. DNA is wrapped around spools of protein, and chemical tags attached to this packaging can silence genes or allow them to be read. A key question has remained: when MYC forces a cell to grow, does it also strip away the chemical "locks" that keep certain genes turned off, effectively unlocking them for the cancer's use?
A team of researchers at Newcastle University set out to answer this question by looking at the relationship between gene activity and DNA packaging across three different types of cancer: breast, liver, and colorectal. They focused on tumors where the MYC gene was highly active and compared them to tumors where it was less active. To ensure their findings were not simply a reflection of how fast the cells were dividing, they carefully adjusted their analysis to account for cell growth rates. By combining data on which genes were turned on with data on the chemical tags attached to the DNA, they searched for a specific pattern: genes that were not only switched on but also had their surrounding DNA stripped of its repressive chemical marks. This combination of high activity and open DNA is a strong signal that the cell is actively using these genes to fuel its growth.
The researchers discovered a consistent group of fifteen genes that appeared in all three cancer types with this specific signature. These genes were turned on and surrounded by open, accessible DNA in tumors with high MYC activity. Among them were genes known to help build ribosomes, the cellular machines that make proteins, as well as genes involved in controlling how DNA is packaged and read. Some of these genes sit on the same stretch of chromosome, suggesting they might be turned on together as a block. The study confirmed that this pattern was not a random occurrence; the overlap of these fifteen genes across three distinct cancers was far greater than what would be expected by chance. This suggests that despite the differences between breast, liver, and bowel cancers, they share a common strategy for using MYC to unlock a specific set of growth-promoting genes.
The team then asked whether these genes were merely passengers in the cancer process or if they were essential for the cancer cells to survive. Using a massive public database that tracks how cancer cells react when specific genes are disabled, they tested the importance of these fifteen genes. The results showed that three of the genes—MYC itself, along with two others named BYSL and BOP1—were critical for the survival of nearly every cancer cell line they tested. These genes are so fundamental that removing them caused the cells to die, regardless of the type of cancer. This indicates that the machinery for making proteins is a universal vulnerability in cancer. Other genes in the group, such as FOXK1 and SLC7A1, were essential only in specific types of cells, suggesting that some cancers rely on these genes more than others depending on their unique environment.
Beyond their role in keeping cancer cells alive, the researchers looked at whether the activity of these genes could predict how a patient would fare. They analyzed survival data from patients with liver cancer and found that high levels of four specific genes from their list—FOXK1, SNHG17, BYSL, and BOP1—were strongly linked to a shorter lifespan. This was a significant finding because the level of the MYC gene itself did not predict survival in the same way. This means that the activity of these downstream genes provides a clearer picture of the disease's severity than simply measuring MYC. The study also found that this group of genes could distinguish cancer tissue from healthy tissue with high accuracy, suggesting they might be useful for diagnosis in the future.
The researchers were careful to note that their work identified a pattern of association rather than proving that one specific event caused another. They adjusted for cell division to ensure the results were specific to MYC activity, but they acknowledged that other factors, such as changes in the number of gene copies, might also play a role. The study establishes a solid foundation of evidence showing that a specific set of fifteen genes is consistently activated and chemically unlocked in MYC-driven cancers. By highlighting which of these genes are essential for the cancer's survival and which ones signal a poor outcome for patients, the research provides a clear map for future studies. It points the way toward new ways of understanding how cancer cells hijack normal biological processes and offers potential targets for therapies that could disrupt the very machinery these tumors rely on to survive.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.